Evidence map›Paper›PMID 36176002›Full record

ReviewJournal of hematology & oncology2022

Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.

Tong Chen, Yuanbo Liu, Yang Wang, Qing Chang, Jinsong Wu, Zhiliang Wang, Daoying Geng, Jin-Tai Yu, Yuan Li, Xiao-Qiu Li and 15 more

Open access · goldAbstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of hematology & oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 65 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Long-term observation of treatment strategies for primary vitreoretinal lymphoma in a multicenter Chinese cohort.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Distinguishing clinical and imaging characteristics of primary central nervous system lymphoma from high-grade glioma and metastatic brain tumors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 11 institutions in 1 country.

Tong ChenDepartment of Hematology, Institute of Medicine, Huashan Hospital, Fudan University, Shanghai, 200040, China. chentong@fudan.edu.cn.
Yuanbo LiuDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Yang WangDepartment of Radiation Oncology, Huashan Hospital, Fudan University, Shanghai, 201107, China.
Qing ChangDepartment of Ophthalmology, Eye and ENT Hospital, Fudan University, Shanghai, 200031, China.
Jinsong WuDepartment of Neurosurgery, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Zhiliang WangDepartment of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Daoying GengDepartment of Radiology, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Jin-Tai YuDepartment of Neurology, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Yuan LiDepartment of Radiology, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Xiao-Qiu LiDepartment of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Hong ChenDepartment of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Dongxiao ZhuangDepartment of Neurosurgery, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Jianyong LiDepartment of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Bin WangDepartment of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Tao JiangDepartment of Neurosurgery, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Lanting LyuSchool of Public Administration and Policy, Health Technology Assessment and Policy Evaluation Group, Renmin University of China, Beijing, 100872, China.
Yuqin SongDepartment of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, 100142, China.
Xiaoguang QiuDepartment of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Wenbin LiDepartment of Neuro-Oncolgoy, Cancer Center, National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Song LinDepartment of Neurosurgery, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Xinghu ZhangDepartment of Neurology, Neuroimmunology and Neuroinfection Center, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China.
Dehong LuDepartment of Pathology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, China.
Junqiang LeiDepartment of Radiology, The First Hospital of Lanzhou University, Lanzhou, 730000, China.
Yaolong ChenResearch Unit of Evidence-Based Evaluation and Guidelines, Chinese Academy of Medical Sciences (2021RU017), School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, China. chenyaolong@lzu.edu.cn.
Ying MaoDepartment of Neurosurgery, National Center for Neurological Disorders, Huashan Hospital, Fudan University, Shanghai, 200040, China. maoying@fudan.edu.cn.
Fudan University · CNCapital Medical University · CNHuashan Hospital · CNBeijing Tian Tan Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNEye & ENT Hospital of Fudan University · CNFirst Hospital of Lanzhou University · CNFudan University Shanghai Cancer Center · CNJiangsu Province Hospital · CNPeking University Cancer Hospital · CNRenmin University of China · CN

Funding

Clinical Research Plan of SHDC SHDC2022CRW004Grant of the National Clinical Research Center for Hematologic Diseases 2020ZKMB03Program for Outstanding Medical Academic Leader of Shanghai 2019LJ05
6 · The paper itself

Abstract

Primary central nervous system lymphoma (PCNSL) is a type of central nervous system restricted non-Hodgkin lymphoma, whose histopathological diagnosis is majorly large B cell lymphoma. To provide specific, evidence-based recommendations for medical professionals and to promote more standardized, effective and safe treatment for patients with PCNSL, a panel of experts from the Chinese Neurosurgical Society of the Chinese Medical Association and the Society of Hematological Malignancies of the Chinese Anti-Cancer Association jointly developed an evidence-based consensus. After comprehensively searching literature and conducting systematic reviews, two rounds of Delphi were conducted to reach consensus on the recommendations as follows: The histopathological specimens of PCNSL patients should be obtained as safely and comprehensively as possible by multimodal tomography-guided biopsy or minimally invasive surgery. Corticosteroids should be withdrawn from, or not be administered to, patients with suspected PCNSL before biopsy if the patient's status permits. MRI (enhanced and DWI) should be performed for diagnosing and evaluating PCNSL patients where whole-body PET-CT be used at necessary time points. Mini-mental status examination can be used to assess cognitive function in the clinical management. Newly diagnosed PCNSL patients should be treated with combined high-dose methotrexate-based regimen and can be treated with a rituximab-inclusive regimen at induction therapy. Autologous stem cell transplantation can be used as a consolidation therapy. Refractory or relapsed PCNSL patients can be treated with ibrutinib with or without high-dose chemotherapy as re-induction therapy. Stereotactic radiosurgery can be used for PCNSL patients with a limited recurrent lesion who were refractory to chemotherapy and have previously received whole-brain radiotherapy. Patients with suspected primary vitreoretinal lymphoma (PVRL) should be diagnosed by vitreous biopsy. PVRL or PCNSL patients with concurrent VRL can be treated with combined systemic and local therapy.

Indexed as

Central Nervous System NeoplasmsHematopoietic Stem Cell TransplantationLymphoma, Non-HodgkinRetinal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCentral Nervous SystemConsensusHumansMethotrexatePositron Emission Tomography Computed TomographyRituximabTransplantation, AutologousVitreous BodyMethotrexateRituximabChinaConsensusManagementPrimary central nervous system lymphoma

Identifiers

PMID36176002
PMCPMC9524012
OpenAlexW4297983405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.